Navigation Links
PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
Date:10/18/2007

Data Presented at the World Muscle Society International Congress

SOUTH PLAINFIELD, N.J., Oct. 18 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced additional data from a Phase 2 clinical trial of PTC124 in patients with Duchenne muscular dystrophy (DMD) due to a nonsense mutation. The results, which include data from all three cohorts of the study, show that administration of PTC124 is associated with qualitative increases in muscle dystrophin expression and with reductions in serum creatine kinase values. These data were presented today at the World Muscle Society (WMS) International Congress in Taormina, Italy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

Patients with DMD are boys and young men who lack dystrophin, a protein that is critical to the structural stability of muscle fibers. This Phase 2 multi-site, open-label, dose-ranging clinical trial enrolled 38 boys with loss of dystrophin due to a nonsense mutation in the dystrophin gene. Participants also had substantially elevated serum creatine kinase levels due to the disease, and symptoms associated with DMD. Boys enrolled in the trial received 28 days of PTC124 treatment at one of three dose levels, with the primary endpoint of the trial being an increase in dystrophin expression in muscle. Pre- and post-treatment muscle biopsies and blood analyses to assess muscle-derived creatine kinase were available from all 38 patients.

An in vitro analysis demonstrated PTC124-induced dystrophin expression in cultured muscle cells from all 35 (100%) of the boys with samples evaluable in this analysis. The in vivo data indicated that, across all three dose levels of PTC124, 18/38 (47%) of patients demonstrated visib
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Sono-Tek Corporation (OTC BB: SOTK) today announced sales of  ... to sales of $2,202,000 for the prior year period, an ... also shown growth over the preceding quarter,s sales, continuing a ... year. Markets that experienced sales increases over the prior year ...
(Date:1/15/2014)... 2014 As health officials across the Midwest warn against ... in Michigan will offer free diagnostic ... Meijer pharmacists to administer tests and, in some cases, fill ... participating in the study. The Grand ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
Breaking Medicine Technology:Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
(Date:7/11/2014)... -- Polio is history in much of the world, ... Pakistan. Giving vaccinated children an extra dose of inactivated ... the highly infectious disease, a new study suggests. ... as early as a year after vaccination. Vaccinated children ... the spread of the disease, according to background information ...
(Date:7/11/2014)... new study challenges the widely held belief that light drinking ... analyzed more than 50 studies that examined drinking habits and ... that those with a form of a gene tied to ... affects how a person,s body breaks down alcohol, resulting in ... variant has been shown to lead to lower drinking over ...
(Date:7/11/2014)... is now providing worldwide clients with the most fashionable ... comes to buying summer wedding dresses online, ladies become ... of beautiful wedding gowns. Recently, the company has launched ... , The company’s current promotion is specially launched ... newest fashion trends. The top experts from AngelWeddingDress want ...
(Date:7/11/2014)... 11, 2014 American Farmer is proud ... Tuesday, July 15, 2014, at 8:30 am ET. , ... proprietary products, which are designed and formulated for use ... learn how these products help the crop realize its ... it is grown. , The show also features UniSouth ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Alliance Labs ... episode of Innovations with Ed Begley Jr, airing later ... times TBA. , In this episode, Innovations will explore ... 100mg docusate sodium in polyethylene glycol base designed to ... how the formulation functions as a hyperosmotic laxative by ...
Breaking Medicine News(10 mins):Health News:Researchers Assess New Way to Boost Polio Immunity 2Health News:A Little Alcohol May Not Be Good for Your Heart After All 2Health News:AngelWeddingDress Will Continuously Unveil More Summer Wedding Dresses for Loyal Clients 2Health News:New Episode of American Farmer Featuring Sunbelt, UniSouth Genetics, and Michigan Milk Producers Association Airing on RFD-TV 2Health News:Alliance Labs & DocuSol® to be Featured in Upcoming Episode of Innovations 2
... Concentra ("Concentra" or the,"Company"), a national leader ... unique combination of medical services and general wellness ... Oregon, is known for its,safe, reliable air transportation ... was searching for an on-site health program that,matched ...
... revenues of $77.8 million, up 11% from,the prior year - Earnings per ... over the second quarter of 2007 - Operating cash flow of ... ... life,sDHA(TM), COLUMBIA, Md., Sept. 5 Martek Biosciences,Corporation (Nasdaq: MATK ...
... BOHEMIA, N.Y., Sept. 5 NBTY, Inc. (NYSE: NTY ), (http://www.NBTY.com ), a leading global manufacturer and marketer of ... follows (amounts,are rounded):, ... ... FOR THE MONTH OF AUGUST ...
... PARIS, Sept. 5 Sanofi-aventis announced the,publication of ... which,demonstrated that dronedarone (MULTAQ(TM)), a new anti-arrhythmic agent ... placebo in,maintaining sinus rhythm while not promoting pro-arrhythmias ... atrial fibrillation,(AF) and atrial flutter (AFL). AF, ...
... trauma patients, study finds , , WEDNESDAY, Sept. 5 (HealthDay ... does not reduce the need for blood transfusions among ... trauma patients. , The drug, epoetin alfa (brand ... because of potentially dangerous side effects. , "Unlike prior ...
... Club and Spa will soon have an East Valley location, ... DMB Executives, another first class Village Health Club and Spa ... Chandler,Arizona. As of July 31st, the land at the corner ... club design has been approved. The,purchase of the 7.3 acres ...
Cached Medicine News:Health News:Concentra Expands Horizon Air Employee Health Program With On-Site Clinic 2Health News:Martek Announces Third Quarter 2007 Financial Results 2Health News:Martek Announces Third Quarter 2007 Financial Results 3Health News:Martek Announces Third Quarter 2007 Financial Results 4Health News:Martek Announces Third Quarter 2007 Financial Results 5Health News:Martek Announces Third Quarter 2007 Financial Results 6Health News:Martek Announces Third Quarter 2007 Financial Results 7Health News:Martek Announces Third Quarter 2007 Financial Results 8Health News:Martek Announces Third Quarter 2007 Financial Results 9Health News:Martek Announces Third Quarter 2007 Financial Results 10Health News:Martek Announces Third Quarter 2007 Financial Results 11Health News:Martek Announces Third Quarter 2007 Financial Results 12Health News:NBTY Announces Preliminary Unaudited Net Sales Results For August 2007 2Health News:NBTY Announces Preliminary Unaudited Net Sales Results For August 2007 3Health News:The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia 2Health News:The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia 3Health News:The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia 4Health News:The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia 5Health News:Controversial Anemia Drug Doesn't Cut Need for Transfusions 2Health News:Controversial Anemia Drug Doesn't Cut Need for Transfusions 3Health News:Ocotillo in Chandler Will Have a Village 2
Inquire...
... Designed for the elegant and ... Avenue collection includes ophthalmic and ... in a variety of shapes ... many face shapes and complexions. ...
... updated styling through the use of innovative ... collection is for the value driven consumer ... Eyewear Collection , The futuristic quality ... of the "strongest and lightest metal on ...
Inquire...
Medicine Products: